Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

Hormone receptor-positive breast cancer (HR+ BC) accounts for approximately 75% of new BC diagnoses. Despite the undisputable progresses obtained in the treatment of HR+ BC in recent years, primary or acquired resistance to endocrine therapies still represents a clinically relevant issue, and is lar...

Full description

Bibliographic Details
Main Authors: Emma Zattarin, Rita Leporati, Francesca Ligorio, Riccardo Lobefaro, Andrea Vingiani, Giancarlo Pruneri, Claudio Vernieri
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cells
Subjects:
breast cancer
hormone receptors
conversion
intratumor heterogeneity
clonal selection
endocrine therapies
Online Access:https://www.mdpi.com/2073-4409/9/12/2644

Internet

https://www.mdpi.com/2073-4409/9/12/2644

Similar Items